Literature DB >> 15328914

p16 expression in squamous lesions of the female genital tract.

Mary M Finegan1, Aaron C Han, Mitchell I Edelson, Norman G Rosenblum.   

Abstract

The aim of this study was to examine the role of p16 in the pathogenesis of squamous carcinoma of the gynecologic tract. Squamous carcinoma and carcinoma in situ from the female genital tract were examined for the expression of p16 by paraffin immunohistochemistry. About 74% (40/54) of cases showed p16 expression. By primary site, 77% (23/30) of cervical, 67% (6/9) of vaginal and 85% (11/13) of vulvar primaries expressed p16, but two endometrial primary squamous carcinomas were negative (0/2). In addition, p16 was not identified in non-dysplastic tissue and low grade dysplasia. In cases where there were matched vaginal or vulvar and cervical primaries in a given patient, there was concordant positive p16 expression. It is concluded that p16 is frequently expressed in squamous carcinoma of the cervix, vagina and vulva, but not seen in cases of benign and low grade lesions. It may be a marker of transformation from a low to a high grade lesion. More cases of endometrial primaries need to be studied to see if these evolve by a p16-independent pathway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15328914     DOI: 10.1023/b:hijo.0000023373.40704.ff

Source DB:  PubMed          Journal:  J Mol Histol        ISSN: 1567-2379            Impact factor:   2.611


  21 in total

1.  Molecular Papanicolaou tests in the twenty-first century: molecular analyses with fluid-based Papanicolaou technology.

Authors:  W M Lin; R Ashfaq; E A Michalopulos; A Maitra; A F Gazdar; C Y Muller
Journal:  Am J Obstet Gynecol       Date:  2000-07       Impact factor: 8.661

2.  Immunohistochemical survey of p16INK4A expression in normal human adult and infant tissues.

Authors:  G P Nielsen; A O Stemmer-Rachamimov; J Shaw; J E Roy; J Koh; D N Louis
Journal:  Lab Invest       Date:  1999-09       Impact factor: 5.662

3.  Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri.

Authors:  R Klaes; T Friedrich; D Spitkovsky; R Ridder; W Rudy; U Petry; G Dallenbach-Hellweg; D Schmidt; M von Knebel Doeberitz
Journal:  Int J Cancer       Date:  2001-04-15       Impact factor: 7.396

4.  Alteration of the CDKN2/p16 gene is not required for HPV-positive uterine cervical cancer cell lines.

Authors:  M Yoshinouchi; A Hongo; N Takamoto; Y Ono; S Nagao; Y Miyagi; T Kudo; J Kodama
Journal:  Int J Oncol       Date:  2000-03       Impact factor: 5.650

5.  Expression of p16INK4 and retinoblastoma protein Rb in vulvar lesions of Chinese women.

Authors:  M K Chan; T H Cheung; T K Chung; S Y Bao; C L Zhao; T Nobori; Y F Wong
Journal:  Gynecol Oncol       Date:  1998-02       Impact factor: 5.482

6.  Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia.

Authors:  J T Keating; A Cviko; S Riethdorf; L Riethdorf; B J Quade; D Sun; S Duensing; E E Sheets; K Munger; C P Crum
Journal:  Am J Surg Pathol       Date:  2001-07       Impact factor: 6.394

Review 7.  Role of the p16 tumor suppressor gene in cancer.

Authors:  W H Liggett; D Sidransky
Journal:  J Clin Oncol       Date:  1998-03       Impact factor: 44.544

8.  Alterations of CDKN2 (MTS1/p16INK4A) gene in paraffin-embedded tumor tissues of human stomach, lung, cervix and liver cancers.

Authors:  J R Kim; S Y Kim; M J Kim; J H Kim
Journal:  Exp Mol Med       Date:  1998-06-30       Impact factor: 8.718

9.  Underexpression of cyclin-dependent kinase (CDK) inhibitors in cervical carcinoma.

Authors:  Y T Kim; N H Cho; S W Park; J W Kim
Journal:  Gynecol Oncol       Date:  1998-10       Impact factor: 5.482

10.  Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation.

Authors:  Y Nakao; X Yang; M Yokoyama; A Ferenczy; S C Tang; M M Pater; A Pater
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.